no effect – Page 6 – Communicable Diseases Research

Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19

Covid-19 치료에서 회복기 혈장의 조기 투여와 후기 투여의 사망률에 미치는 영향

Article

Published on 2021-08-012022-09-11
Journal: Transfusion and apheresis science : official journ [Category] SARS, 치료법, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration age antibody Care city clinical and laboratory parameters Comorbidities Comorbidity consecutive patient convalescent plasma coronavirus COVID-19 diagnosed drug Drug administration Effect effective FIVE food Gender had no Hospitalization ICU ICU admission Infection intensive care intensive care unit laboratory confirmation laboratory parameter Laboratory parameters limitations lung tomography mechanical ventilator Mortality no difference no effect no significant difference no significant differences pandemic Patient patients reported SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 severity Spread Support the disease Treatment two group two groups U.S. Food and Drug Administration Wuhan Wuhan, China
[DOI] 10.1016/j.transci.2021.103148 PMC 바로가기 [Article Type] Article

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial

Covid-19에서 회복기 혈장이 무의미합니까?회복 무작위 대조 시험의 베이지안 재분석

Randomized Controlled Trial

Published on 2021-08-012022-08-13
Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 임상, 치료기술,

[키워드] absence analysed antibody Antibody Response Bayesian Bayesian analyses Bayesian analysis Bayesian method Bayesian methods Bayesian re-analysis benefit chance convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 detectable evaluated Evidence evidence of had no Highlights hypothesis test hypothesis tests likelihood misuse Mortality no effect no evidence of Patient patients patients hospitalized percentage point performed Perspective plasma posterior probability presenting Probability Randomized controlled trial recovery RECOVERY trial reduce reduction in reported Result risk risk difference serology seronegative seronegative patient seronegative patients serostatus Symptoms treat Trial variety was performed witness
[DOI] 10.1016/j.ijid.2021.06.034 PMC 바로가기 [Article Type] Randomized Controlled Trial

Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study

Clinical Science

Published on 2021-07-252022-10-28
Journal: Rheumatology (Oxford, England) [Category] COVID-19,

Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19

ACE2 활동에 대한 Hydroxychloroquine의 조절 효과의 특성 : Covid-19와 관련된 새로운 통찰력

Research Article

Published on 2021-07-232022-09-10
Journal: BioMed Research International [Category] 치료제,

Perceived Ageism During the Covid-19-Crisis Is Longitudinally Related to Subjective Perceptions of Aging

Public Health

Published on 2021-07-132022-10-31
Journal: Frontiers in Public Health [Category] Coronavirus, MERS, SARS,

Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin

이버멕틴에 의한 SARS-CoV-2 감염 중 임상 및 면역학적 결과의 약화

Article

Published on 2021-07-122022-09-11
Journal: EMBO Molecular Medicine [Category] MERS, SARS, 변종,

[키워드] airway airways Analysis Anosmia antigenic variant antigenic variants antiviral activity attenuation caused clinical condition Clinical deterioration coronavirus COVID‐19 dampen death disease distress Efficacy golden hamsters hamsters Host immunological immunology immunomodulatory activity immunomodulatory drug immunomodulatory drugs IMPROVE induce Inflammation inflammatory pathways Inflammatory response Ivermectin lead limit Lower respiratory tract lung lung tissue Macrophage Microbiology, Virology & Host Pathogen Interaction modulate modulating modulation no effect olfactory outcome pandemic pathophysiology pathway patients Prevent promote pulmonary symptoms reduce respiratory respiratory distress response SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2‐infected SARS‐CoV‐2 Severe case severe cases severity Standard dose Support the disease therapy transcriptomic Transcriptomic analyses type I interferon upper and lower respiratory tracts Vaccine Viral viral infections Viral load
[DOI] 10.15252/emmm.202114122 PMC 바로가기 [Article Type] Article

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

DPP-4 억제제 및 COVID-19의 결과에 대한 상충되는 증거 풀기: 내러티브 검토 및 메타 분석

Meta-Analysis

Published on 2021-07-012022-09-11
Journal: Journal of Endocrinological Investigation [Category] SARS, 바이오마커,

[키워드] 95% CI absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse outcome association Cell conducted coronavirus coronavirus disease Coronavirus disease-19 COVID-19 diabetes Diabetes Mellitus dipeptidyl peptidase Dipeptidyl peptidase-4 DPP4 Epidemiology Evidence immune system Inconclusive increase Incretins independent risk factor Infection inhibitor Meta-analysis Mortality mortality rate Neutral no effect observational studies observational study outcome outcomes pandemic Patient provide Randomized controlled trials Regulation reported Research respiratory respiratory tract risk risk ratio SARS-CoV-2 severe acute respiratory syndrome Coronavirus shown significantly lower Spread suggested systematic review Topic Treatment while
[DOI] 10.1007/s40618-021-01515-6 PMC 바로가기 [Article Type] Meta-Analysis

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy

Research Article

Published on 2021-06-282022-10-28
Journal: PLoS ONE [Category] COVID-19,

Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis

Review

Published on 2021-06-132022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

중증 SARS-CoV-2 감염으로 입원한 환자에서 회복기 혈장의 강력한 중화항체 효과

Randomized Controlled Trial

Published on 2021-05-272022-08-13
Journal: Nature Communications [Category] SARS, 바이오마커, 임상, 진단, 치료기술, 치료법, 치료제,

[키워드] approach autologous humoral response benefit clinical benefit comparable convalescent plasma Course COVID-19 COVID-19 patient COVID-19 patients Cytokines decision disease course donors drug Effect ENhance focus Hospital admission hospitalized COVID-19 patient Immunological response IMPROVE Infection majority neutralizing antibody neutralizing SARS-CoV-2 antibodies neutralizing SARS-CoV-2 antibody no effect Patient patients hospitalized plasma proinflammatory cytokines randomized clinical trial respiratory respiratory tract Safe SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection selected serum proinflammatory cytokine serum proinflammatory cytokines severe SARS-CoV-2 standard care survival the disease translational Translational research treat treated Treatment treatment for COVID-19 Trial Viral viral clearance viral infection Virological virological and immunological responses
[DOI] 10.1038/s41467-021-23469-2 PMC 바로가기 [Article Type] Randomized Controlled Trial